Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)
- Registration Number
- NCT03608657
- Lead Sponsor
- Amgen
- Brief Summary
This will be a Canadian observational study utilizing a prospective cohort design. Patients with active psoriatic arthritis (PsA) for whom the treating physician has decided, prior to and independently of enrollment in the study, to initiate treatment with Otezla® will be considered for participation in the study.
Patients will be enrolled from the practices of predominantly community rheumatologists and will be followed for 12 months from the time of initiation of treatment with Otezla® In line with the observational nature of the study, there will be no protocol imposed tests or assessments. However, recommended follow up visits will be at 4, 8 and 12 months. In addition, patients may be asked to voluntarily complete self-administered questionnaires.
The 24-month assessment will be aimed to determine whether or not treatment with Otezla® has been maintained, and if not, to ascertain the reason for discontinuation and what new treatment was initiated following discontinuation of Otezla®
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 102
- Active psoriatic arthritis (PsA) as per the Classification criteria for Psoriatic Arthritis (CASPAR) criteria, based on the investigator's clinical judgement.
- Adult patients (≥18 years of age) with PsA
- Prescribing physician has decided to initiate treatment with Otezla®, and this decision was prior to and independent of patient enrollment in the study.
- Access to commercially available Otezla®
- Patients who are pregnant, breastfeeding, or who are planning on becoming pregnant during the course of the study
- Participation in Investigational Clinical Trial within the last 60 days.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Psoriatic Arthritis patients treated with Apremilast Apremilast Active PsA as per the CASPAR criteria, based on the investigator's clinical judgement with access to commercially available Otezla
- Primary Outcome Measures
Name Time Method The rate of achieving Low Disease Activity (LDA) Up to approximately 1 year Is defined as Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) \< 14. cDAPSA is calculated as the sum of TJC - 68, SJC - 66, PtGA (10-cm VAS) and Pain (10-cm VAS).
- Secondary Outcome Measures
Name Time Method Medical Outcomes Study Short- Form 36 (SF-36) Up to approximately 1 year A generic quality of life index that is comprised of 36 items converging to eight (8) domains: Vitality, Physical Functioning, Bodily Pain, General Health Perception, Physical Role Functioning, Emotional Role Functioning, Social Role Functioning, and Mental Health
Tender Joint Count (TJC) Up to Approximately 1 year Based on 68/66 joints to determine joint pain/tenderness and joint swelling, as conducted during the physical examination and per the practices of the treating physician
Patient-reported adherence with PsA treatment from the last visit. Up to approximately 1 year An optional weekly take-home diary will be offered to patients; this diary will aid in documenting how many doses (if any) of PsA treatment were missed, and the reason(s) why.
Proportion of patients in Patient Acceptable Symptom State (PASS) Up to approximately 1 year A single question phrased as "If you were to remain for the next few months as you were during the last week, would this be acceptable or unacceptable to you?" with a binary (Yes or No) response
Adverse Events (AEs) From enrollment until at least 28 days after completion of study treatment Number of subjects with adverse events
Swollen Joint Count (SJC) Up to Approximately 1 year Based on 68/66 joints to determine joint pain/tenderness and joint swelling, as conducted during the physical examination and per the practices of the treating physician
Assessment of Body Surface Area (BSA) Up to approximately 1 year height (cm) x weight (kg)/3600)½
Health Assessment Questionnaire Disability Index (HAQ-DI) Up to approximately 1 year This is a self-administered questionnaire measuring the patient's functional ability during the last week. It consists of 20 items converging to 8 scales measuring dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. The patients rate each activity as 0 = without any difficulty, 1 = some difficulty, 2 = much difficulty and 4 = unable. The final score ranges from 0 to 3 with higher scores indicating more disability.
Physician global assessment of disease activity (MDGA) Up to approximately 1 year This is a 100-mm visual analog scale (VAS) with 0 indicating lowest disease and 100 highest disease activities
The rate of achieving Low Disease Activity (LDA) Up to approximately 8 months Is defined as Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) \< 14. cDAPSA is calculated as the sum of TJC - 68, SJC - 66, PtGA (10-cm VAS) and Pain (10-cm VAS).
Assessment of Enthesitis (Leeds Enthesitis Index (LEI) Up to Approximately 1 year This is completed by the treating physician and assesses tenderness at six (6) sites, specifically two (2) lateral at the following: epicondyles of the humerus, medial condyles of the femur and the insertion of the Achilles tendon. The LEI is scored between 0 and 6. Resolution versus improvement versus no change versus worsening of enthesitis since the last available assessment
Assessment of Dactylitis (Leeds Dactylitis Index) Up to approximately 1 year Resolution versus improvement versus no change versus worsening of dactylitis since the last available assessment
Patient global assessment of disease activity (PtGA) Up to approximately 1 year This is a 100-mm VAS with 0 indicating lowest disease and 100 highest disease activity
Treatment Satisfaction Questionnaire for Medication (TSQM) Up to approximately 1 year This is a 14-item questionnaire evaluating patient satisfaction in terms of the following: effectiveness, side effects, convenience, and global satisfaction
Patient subjective assessment of Pain using a 100mm VAS Up to approximately 1 year Patient subjective assessment of Pain using a 100mm VAS
Psoriatic Arthritis (WPAI:PsA) Up to approximately 1 year A 6-item questionnaire assessing the effect of PsA on the patient's ability to work and perform daily activities. It assesses presenteeism, absenteeism, productivity and activity impairment
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (19)
The Waterside Clinic
🇨🇦Barrie, Canada
The Arthritis and Osteoporosis Centre
🇨🇦Burlington, Canada
Adachi Medicine Professional Corporation
🇨🇦Hamilton, Canada
Credit Valley Rheumatology
🇨🇦Mississauga, Canada
Institut de Recherche en Rhumatologie de Montréal
🇨🇦Montreal, Canada
Applied Medical Informatics Research Inc. (A.M.I.R.)
🇨🇦Montreal, Canada
Brent Appleton Clinic New Westminster
🇨🇦New Westminster, Canada
Dr. A. M. Jaroszynska Rheumatology and Osteoporosis Clinic
🇨🇦Oakville, Canada
Drs M&W Teo
🇨🇦Penticton, Canada
Groupe de recherche en maladies osseuses Inc.
🇨🇦Quebec, Canada
Scroll for more (9 remaining)The Waterside Clinic🇨🇦Barrie, Canada